UMB Bank n.a. lifted its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 34.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,041 shares of the company’s stock after buying an additional 4,153 shares during the period. UMB Bank n.a.’s holdings in AstraZeneca were worth $1,051,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of the stock. Frank Rimerman Advisors LLC increased its position in shares of AstraZeneca by 25,673.7% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 9,794 shares of the company’s stock worth $764,000 after purchasing an additional 9,756 shares in the last quarter. 1832 Asset Management L.P. raised its stake in shares of AstraZeneca by 7.0% in the second quarter. 1832 Asset Management L.P. now owns 65,772 shares of the company’s stock valued at $5,130,000 after acquiring an additional 4,280 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of AstraZeneca by 15.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 6,117 shares of the company’s stock worth $484,000 after acquiring an additional 800 shares in the last quarter. Evergreen Capital Management LLC boosted its holdings in shares of AstraZeneca by 6.7% in the 2nd quarter. Evergreen Capital Management LLC now owns 20,231 shares of the company’s stock worth $1,578,000 after acquiring an additional 1,270 shares in the last quarter. Finally, Bank of Montreal Can grew its position in AstraZeneca by 35.5% during the 2nd quarter. Bank of Montreal Can now owns 1,465,575 shares of the company’s stock worth $116,924,000 after acquiring an additional 384,308 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.
AstraZeneca Price Performance
Shares of AZN stock opened at $67.96 on Wednesday. The firm has a market cap of $210.75 billion, a price-to-earnings ratio of 32.52, a PEG ratio of 1.04 and a beta of 0.46. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a 50-day moving average price of $66.14 and a 200 day moving average price of $74.39.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on AZN shares. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $89.75.
Read Our Latest Research Report on AstraZeneca
AstraZeneca Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
- Five stocks we like better than AstraZeneca
- 3 Grocery Stocks That Are Proving They Are Still Essential
- SAP’s Strong Momentum: A Bullish Setup for Investors
- What does consumer price index measure?
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Why is the Ex-Dividend Date Significant to Investors?
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.